Kyverna Therapeutics (KYTX) Stock Forecast & Price Target

$4.12 +0.04 (+0.98%)

(As of 11/20/2024 ET)

Kyverna Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 9 Analyst Ratings

Sell
0

Hold
1

Buy
8

Based on 9 Wall Street analysts who have issued ratings for Kyverna Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 9 analysts, 1 has given a hold rating, 7 have given a buy rating, and 1 has given a strong buy rating for KYTX.

Consensus Price Target

$25.71
524.13% Upside

According to the 9 analysts' twelve-month price targets for Kyverna Therapeutics, the average price target is $25.71. The highest price target for KYTX is $48.00, while the lowest price target for KYTX is $6.00. The average price target represents a forecasted upside of 524.13% from the current price of $4.12.

Get the Latest News and Ratings for KYTX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Kyverna Therapeutics and its competitors.

KYTX Analyst Ratings Over Time

Type	Current Forecast 11/22/23 to 11/21/24	1 Month Ago 10/23/23 to 10/22/24	3 Months Ago 8/24/23 to 8/23/24	1 Year Ago 11/22/22 to 11/22/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	N/A
Buy	7 Buy rating(s)	7 Buy rating(s)	5 Buy rating(s)	N/A
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	N/A
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	N/A
Consensus Price Target	$25.71	$28.71	$34.40	N/A
Forecasted Upside	524.13% Upside	452.20% Upside	325.22% Upside	N/A
Consensus Rating	Buy	Buy	Moderate Buy	N/A

“Fed Proof” Your Bank Account with THESE 4 Simple Steps (Ad)

Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.

Learn these 4 simple steps and protect your savings before it’s too late.

KYTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

KYTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Kyverna Therapeutics Stock vs. The Competition

Type	Kyverna Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.80	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	524.13% Upside	26,904.61% Upside	9.81% Upside
News Sentiment Rating	Neutral News See Recent KYTX News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/20/2024	HC Wainwright 2 of 5 stars	M. Kapoor Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Neutral ➝ Neutral	$7.00 ➝ $6.00	+47.06%
11/15/2024	Wells Fargo & Company 3 of 5 stars		Lower Target	Overweight ➝ Overweight	$44.00 ➝ $24.00	+442.99%
10/10/2024	UBS Group 4 of 5 stars	T. Huynh Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$13.00	+188.25%
10/9/2024	RODMAN&RENSHAW Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Butler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
10/9/2024	Rodman & Renshaw Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$16.00	+247.83%
7/31/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$39.00 ➝ $33.00	+282.83%
3/4/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Smith Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
3/4/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$48.00	+72.97%
3/4/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$40.00	+44.14%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 03:35 AM ET.

KYTX Forecast - Frequently Asked Questions

: According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Kyverna Therapeutics is $25.71, with a high forecast of $48.00 and a low forecast of $6.00.
: 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kyverna Therapeutics in the last year. There is currently 1 hold rating, 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" KYTX shares.
: According to analysts, Kyverna Therapeutics's stock has a predicted upside of 524.13% based on their 12-month stock forecasts.
: Over the previous 90 days, Kyverna Therapeutics's stock had 1 upgrade by analysts.
: Kyverna Therapeutics has been rated by research analysts at HC Wainwright, Rodman & Renshaw, RODMAN&RENSHAW, UBS Group, and Wells Fargo & Company in the past 90 days.
: Analysts like Kyverna Therapeutics more than other "medical" companies. The consensus rating for Kyverna Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how KYTX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

“Fed Proof” Your Bank Account with THESE 4 Simple Steps (Ad)

Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.

Learn these 4 simple steps and protect your savings before it’s too late.

This page (NASDAQ:KYTX) was last updated on 11/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kyverna Therapeutics (KYTX) Stock Forecast & Price Target